GSK Jan 2025 40.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:38PM EDT. Market open.
| Previous close | 2.5500 |
| Open | 2.5500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 40.00 |
| Expiry date | 2025-01-17 |
| Day's range | 2.3500 - 2.5500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Yahoo FinanceAmazon Health: A long play and a search for partners
Amazon Pharmacy is just one of the segments of health that the e-retail giant is pursuing.
ZacksIncyte (INCY) Down on FDA Nod for Another Myelofibrosis Drug
Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.
- Investing.com
FDA approves GSK's unique myelofibrosis treatment Ojjaara
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (NYSE:GSK) novel treatment, Ojjaara (momelotinib), for adults with intermediate- or high-risk myelofibrosis and anemia. This announcement comes after a three-month delay due to the need for additional data review.
© 2023 Yahoo. All rights reserved.
